Headlines about Immune Design (NASDAQ:IMDZ) have trended somewhat positive this week, according to Accern. The research firm scores the sentiment of press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Immune Design earned a daily sentiment score of 0.11 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 47.5446240534417 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Immune Design (NASDAQ IMDZ) traded down $0.25 during trading on Wednesday, hitting $4.00. The company had a trading volume of 1,111,000 shares, compared to its average volume of 300,260. Immune Design has a 12-month low of $3.78 and a 12-month high of $13.05.

Immune Design (NASDAQ:IMDZ) last posted its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($0.52) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.63) by $0.11. Immune Design had a negative return on equity of 68.69% and a negative net margin of 619.62%. The firm had revenue of $0.52 million for the quarter, compared to the consensus estimate of $0.62 million. research analysts anticipate that Immune Design will post -1.89 EPS for the current year.

A number of research firms recently weighed in on IMDZ. BidaskClub downgraded Immune Design from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 5th. Royal Bank Of Canada began coverage on Immune Design in a research note on Thursday, September 14th. They issued an “outperform” rating and a $20.00 price target on the stock. Zacks Investment Research downgraded Immune Design from a “buy” rating to a “hold” rating in a research note on Friday, November 10th. ValuEngine upgraded Immune Design from a “sell” rating to a “hold” rating in a research note on Friday, August 11th. Finally, Wells Fargo & Company downgraded Immune Design from an “outperform” rating to a “market perform” rating and decreased their price target for the company from $29.00 to $10.00 in a research note on Tuesday, October 17th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $13.19.

In other news, major shareholder Leo Guthart acquired 2,439,000 shares of Immune Design stock in a transaction that occurred on Friday, October 27th. The stock was purchased at an average cost of $4.10 per share, with a total value of $9,999,900.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Peter Svennilson acquired 2,681,000 shares of Immune Design stock in a transaction that occurred on Friday, October 27th. The shares were purchased at an average cost of $4.10 per share, with a total value of $10,992,100.00. The disclosure for this purchase can be found here. Over the last 90 days, insiders purchased 5,300,000 shares of company stock worth $21,874,900. Company insiders own 20.70% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This story was first posted by Watch List News and is the property of of Watch List News. If you are accessing this story on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.watchlistnews.com/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-immune-design-imdz-stock-price/1733095.html.

Immune Design Company Profile

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.

Insider Buying and Selling by Quarter for Immune Design (NASDAQ:IMDZ)

Receive News & Ratings for Immune Design Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.